Solid Biosciences Reports Positive Initial Clinical Data

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences, announced positive initial results from INSPIRE DUCHENNE, their next-generation gene therapy clinical study of SGT-003. Interim 90-day biopsy data reported in the first three participants showed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple biomarkers that are indicators of muscle health and resilience. SGT-003 has been well-tolerated across the six patients dosed to date. No serious adverse events (SAEs) were observed. There are currently six active clinical trial sites across the United States and Canada, and they have regulatory approvals to expand to the U.K. and Italy. In mid-2025, the Company plans to request a meeting with the FDA to discuss the potential accelerated approval pathway for SGT-003.

PRESS RELEASE: https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-reports-positive-initial-clinical-data-next

COMMUNITY LETTER: https://www.solidbio.com/letter-to-the-duchenne-community-inspire-duchenne-positive-initial-clinical-trial-data/